Similar articles for PMID: 7876648

Year	Number of Results
1990	1
1991	1
1992	18
1993	17
1994	21
1995	26
1996	18
1997	18
1998	22
1999	14
2000	13
2001	3
2002	5
2003	2
2004	2
2005	2
2006	1
2007	1
2008	1
2012	1
2013	1
2017	2
2018	1
2020	3
2021	2
2024	0

1

Clinical experience with an inactivated hepatitis A vaccine.

Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clemens R, et al. J Infect Dis. 1995 Mar;171 Suppl 1:S44-9. doi: 10.1093/infdis/171.supplement_1.s44. J Infect Dis. 1995. PMID: 7876648 Review.

2

Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity.

Van Damme P, Matheï C, Thoelen S, Meheus A, Safary A, André FE. Van Damme P, et al. J Med Virol. 1994 Dec;44(4):435-41. doi: 10.1002/jmv.1890440422. J Med Virol. 1994. PMID: 7897376 Clinical Trial.

3

Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.

Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Van Damme P, et al. J Med Virol. 1994 Dec;44(4):446-51. doi: 10.1002/jmv.1890440425. J Med Virol. 1994. PMID: 7897379 Clinical Trial.

4

Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals.

Sandman L, Davidson M, Krugman S. Sandman L, et al. J Infect Dis. 1995 Mar;171 Suppl 1:S50-2. doi: 10.1093/infdis/171.supplement_1.s50. J Infect Dis. 1995. PMID: 7876649 Clinical Trial.

5

Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later.

Briem H, Safary A. Briem H, et al. J Med Virol. 1994 Dec;44(4):443-5. doi: 10.1002/jmv.1890440424. J Med Virol. 1994. PMID: 7897378 Clinical Trial.

6

Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.

Theilmann L, Kallinowski B, Gmelin K, Hofmann F, Scheiermann N, Wohland B, Stickl H, Maiwald H, Moriabadi FK, Bock HL, et al. Theilmann L, et al. Vaccine. 1992;10 Suppl 1:S132-4. doi: 10.1016/0264-410x(92)90567-4. Vaccine. 1992. PMID: 1335644 Clinical Trial.

7

Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters.

Lee SD, Chan CY, Yu MI, Wang YJ, Lo KJ, Safary A. Lee SD, et al. Am J Gastroenterol. 1996 Jul;91(7):1360-2. Am J Gastroenterol. 1996. PMID: 8677995

8

Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A.

Zuckerman JN, Kirkpatrick CT, Huang M. Zuckerman JN, et al. J Travel Med. 1998 Mar;5(1):18-22. doi: 10.1111/j.1708-8305.1998.tb00450.x. J Travel Med. 1998. PMID: 9772311 Free article. Clinical Trial.

9

Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children.

Balcarek KB, Bagley MR, Pass RF, Schiff ER, Krause DS. Balcarek KB, et al. J Infect Dis. 1995 Mar;171 Suppl 1:S70-2. doi: 10.1093/infdis/171.supplement_1.s70. J Infect Dis. 1995. PMID: 7876652 Clinical Trial.

10

Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children.

Newcomer W, Rivin B, Reid R, Moulton LH, Wolff M, Croll J, Johnson C, Brown L, Nalin D, Santosham M. Newcomer W, et al. Pediatr Infect Dis J. 1994 Jul;13(7):640-2. doi: 10.1097/00006454-199407000-00011. Pediatr Infect Dis J. 1994. PMID: 7970954 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

195 results

Results by year